Apr 01, 2021 8:00am EDT Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
Mar 02, 2021 8:05am EST Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference
Feb 22, 2021 8:05am EST Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference
Feb 17, 2021 8:05am EST Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders
Jan 04, 2021 8:01am EST Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer
Dec 22, 2020 6:25pm EST Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering
Dec 03, 2020 8:30am EST Inhibikase Advances Development Program for Multiple System Atrophy (MSA) Based on Demonstration of Key Role of c-Abl Kinase in MSA Neurodegeneration
Jul 27, 2020 11:28am EDT Inhibikase Files Registration Statement for Proposed Initial Public Offering
Apr 09, 2019 8:00am EDT Inhibikase Therapeutics Announces Appointment of Elizabeth O’Farrell to its Board of Directors
